We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes (TDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00849563
Recruitment Status : Completed
First Posted : February 24, 2009
Last Update Posted : April 10, 2014
Sponsor:
Collaborator:
deCODE genetics
Information provided by (Responsible Party):
Duke University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of the study is to assess the clinical utility of a genetic test for Type 2 diabetes risk in combination with standardized risk assessment compared with standardized risk assessment alone, and to measure whether changes in perceived risk following genetic testing for Type 2 diabetes risk are correlated with behavior change and increased concern about risk for Type 2 diabetes.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Other: Standardized Risk Assessment Not Applicable

Detailed Description:

One thousand outpatients will be enrolled over two years at two university-affiliated primary care clinics. Patients will be assigned to one of three study arms: those who want genetic testing for diabetes risk will be randomly assigned to either receive the testing in addition to the SRA (SRA+G) or to receive the SRA only (SRA-only). Those who do not wish to have genetic testing will receive the SRA only. All patients will be surveyed at baseline, immediately after going through the SRA (risk-counseling visit; 2-4 weeks after initial visit), at 3 months post risk counseling visit and at 12 months post risk counseling visit. BMI, waist circumference, fasting plasma glucose and insulin will be measured at baseline and 12 months. Surveys will allow us to track patients' emotional responses to diabetes risk information and changing perceptions of personal risk for Type 2 diabetes over time, and to see if these correlate with subsequent diet and exercise behaviors.

We will use a linear model to assess the effects of genetic testing among the three study groups, using HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR) and weight loss as the primary outcomes. We will use generalized linear ordinal regression models to fit the ordinal survey outcomes of risk perceptions to the continuous HOMA-IR and weight outcome variables.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes
Study Start Date : April 2009
Actual Primary Completion Date : September 2011
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genetic Testing

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: SRA+genetic test
patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
 Other: Standardized Risk Assessment
patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
No Intervention: SRA only
Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
No Intervention: no testing control
Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of weight loss [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Change in perceptions of personal risk for Type 2 diabetes [ Time Frame: 12 months ]
  2. Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR) [ Time Frame: 12 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Are male or female outpatients
  • No self-reported history of diabetes
  • No self-reported history of prior genetic testing for diabetes
  • Not pregnant (self report)
  • Are ≥18 and <81 years of age
  • Scheduled to receive serum glucose test in participating clinic
  • Fasting at time of blood draw (no food or drink - except water - previous 8 hours: self report)
  • Able and willing to give legally effective consent
  • Able and willing to participate in patient questionnaires
  • Ambulatory

Exclusion Criteria:

  • Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening
  • Self-report of current or prior diabetes diagnosis
  • Self-reported prior history of genetic testing for diabetes
  • Baseline serum glucose test result >125
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00849563


Locations
Layout table for location information
United States, North Carolina
Duke Family Medicine at Pickens
Durham, North Carolina, United States, 27705
Duke Health Center at Pickett Rd
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
deCODE genetics
Investigators
Layout table for investigator information
Principal Investigator: Geoffrey Ginsburg, Md, PhD Institute for Genome Sciences and Policy, Duke University
Principal Investigator: Alex Cho, MD Institute for Genome Sciences and Policy, Duke University
Principal Investigator: Scott Joy, MD Duke University
Principal Investigator: Susanne Haga, PhD Institute for Genome Sciences and Policy, Duke University
Principal Investigator: Isaac Lipkus, PhD Institute for Genome Sciences and Policy, Duke University
Principal Investigator: Gloria Trujillo, MD Duke University
Principal Investigator: Julianne O'Daniel, PhD Institute for Genome Sciences and Policy, Duke University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00849563    
Other Study ID Numbers: Pro00011592
First Posted: February 24, 2009    Key Record Dates
Last Update Posted: April 10, 2014
Last Verified: April 2014
Keywords provided by Duke University:
predictive genomics
personalized medicine
personal genomics
genetic knowledge
 genetic attitudes
prevention
health outcomes
behavioral
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases